RECRUITING Not applicable ClinicalTrials.gov

rTMS as an Intervention for Levodopa-induced Dyskinesia

Sponsor: Danish Research Centre for Magnetic Resonance • ClinicalTrials.gov ID: NCT06570824

Registry updated: 2026-08-27

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.

Interventions

active TMS (Device)
Transcranial magnetic stimulation using MagVenture XP Orange Stimulator using active side of MagVenture Cool-B70 coil
sham TMS (Device)
Sham transcranial magnetic stimulation using MagVenture XP Orange Stimulator, flipping the active side of the MagVenture Cool-B70 coil

Eligibility criteria

Inclusion Criteria: * Clinically established or probable PD * Clinical Diagnostic Criteria for Parkinson's Disease * Peak-of-dose levodopa-induced dyskinesia. * Stable antiparkinsonian medicine for at least four weeks. * Signed informed consent. Exclusion Criteria: * Psychiatric disorders. * Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin). * Regular usage of benzodiazepines and opioids (more than once per week). * History of neurological disease other than Parkinson's disease. * History of epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Contraindications for MRI scan * Female participants of childbearing age must not be pregnant and that they must use contraception during the trial. * Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.

Conditions

Dyskinesia, Drug-Induced Parkinson Disease

Locations

DRCMR — Hvidovre, Denmark

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment